Evidence map›Paper›PMID 38993683›Full record

ArticleBladder cancer (Amsterdam, Netherlands)2022

Loss of

Nur Faezah Binti Ismail, Mona Foth, Amal Rahil Elgaddafi Yousef, Ningxuan Cui, Joshua D G Leach, Thomas Jamieson, Saadia A Karim, Jonathan M Salmond, Jennifer P Morton, Tomoko Iwata

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nur Faezah Binti IsmailSchool of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Mona FothSchool of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Amal Rahil Elgaddafi YousefSchool of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Ningxuan CuiSchool of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Joshua D G LeachCancer Research UK Beatson Institute, Glasgow, UK.
Thomas JamiesonCancer Research UK Beatson Institute, Glasgow, UK.
Saadia A KarimCancer Research UK Beatson Institute, Glasgow, UK.
Jonathan M SalmondDepartment of Pathology, Queen Elizabeth University Hospital, Glasgow, UK.
Jennifer P MortonCancer Research UK Beatson Institute, Glasgow, UK.
Tomoko IwataSchool of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCXCR2 is a chemokine receptor expressed in myeloid cells, including neutrophils and macrophages. Pharmacological inhibition of CXCR2 has been shown to sensitize tumours to immune checkpoint inhibitor immunotherapies in some cancer types.

objectiveTo investigate the effects of

methodsUrothelial pathogenesis and immune contexture was investigated in an OH-BBN model of invasive bladder cancer with

resultsUrothelial tumour pathogenesis was significantly increased upon

conclusionsIn contrast to previous reports of increased CXCR2 signalling associated with disease progression and poor prognosis, CXCR2 was protective against bladder cancer during tumour initiation. This is likely due to a suppression of acute inflammation. The strategy for sensitizing checkpoint immunotherapy by CXCR2 inhibition in bladder cancer may benefit from an examination of immune suppressive status.

Indexed as

chemokine receptorsimal modelsimmunosuppressiontumour infiltrating lymphocytesUrinary bladder neoplasms

Identifiers

PMID38993683
PMCPMC11181715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.